Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Analysis & Investment Frameworks
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock analysis on Invetso. Review Anbio Biotechnology Class A Ordinary Shares’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Anbio Biotechnology Class A Ordinary Shares Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: DE
Anbio Biotechnology Class A Ordinary Shares Key Financial Metrics
- Market Cap: $170.74M
- Revenue: $8.65M
- P/E Ratio: 25.93
- ROE: 27.49%
- ROIC: 25.46%
- Dividend Yield: N/A
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.